(Q46974757)

27 December 2017

title

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience (English)

1 reference

27 December 2017

1 reference

Athanasios Dimopoulos

10

1 reference

27 December 2017

George Fountzilas

2

George Fountzilas

1 reference

27 December 2017

Dimitrios Pectasides

1

Dimitrios Pectasides

1 reference

27 December 2017

Gerassimos Aravantinos

3

Gerassimos Aravantinos

1 reference

27 December 2017

Theofanis Economopoulos

9

Theofanis Economopoulos

1 reference

27 December 2017

Dimitrios Farmakis

6

Dimitrios Farmakis

1 reference

27 December 2017

Nikolaos Pavlidis

8

Nikolaos Pavlidis

1 reference

27 December 2017

author name string

Charalambos Kalofonos

4

1 reference

27 December 2017

Helen Efstathiou

5

1 reference

27 December 2017

Dimosthenes Skarlos

7

1 reference

27 December 2017

language of work or name

English

0 references

publication date

3 March 2006

1 reference

27 December 2017

published in

Gynecologic Oncology

1 reference

27 December 2017

volume

102

1 reference

27 December 2017

page(s)

285-291

1 reference

27 December 2017

issue

2

1 reference

27 December 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell carcinoma of the ovary: a study of 59 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clinical characteristics of clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell carcinoma of the ovary.Light and electron microscopic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Clear cell ovarian adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Survival among U.S. women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Ovarian adenocarcinoma of mesonephric type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Survival probability in ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.038

10.1016/J.YGYNO.2005.12.038

7 January 2021

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

16516283

1 reference

27 December 2017